|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | C07D 223/16 | |
| A61K 31/55 | |||
| A61P 3/04 |
| (11) | Patento numeris | 2332921 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10010301.9 |
| Europos patento paraiškos padavimo data | 2004-06-16 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-06-15 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2016-03-02 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 479280 P | 2003-06-17 | US | |
| 512967 P | 2003-10-21 | US |
| (72) |
Throop, Beverly W., US
Gilson, Charles A., III., US
Aytes, Shelley, US
Estrade, Scott A., US
Sengupta, Dipanjan, US
Smith, Brian, US
Rey, Max, CH
Weigl, Ulrich, DE
|
| (73) |
Arena Pharmaceuticals, Inc.,
6154 Nancy Ridge Drive, San Diego, CA 92121,
US
|
| (54) | 8-Chloro-1 -methyl-2,3,4,5-tetrahydro-1 H-3benzazapine Hydrochloride |
| 8-Chloro-1 -methyl-2,3,4,5-tetrahydro-1 H-3benzazapine Hydrochloride |